Navigation Links
Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
Date:9/22/2008

Live Audio Webcast Thursday, September 25, 2008

SAN DIEGO, Sept. 22 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences will be presenting at the UBS Global Life Sciences Conference at the Grand Hyatt in New York.

The live presentation takes place Thursday, September 25, 2008 at 10:00 a.m. Eastern Time (ET) /7:00 a.m. Pacific Time (PT). The presentation will be simultaneously webcast and may be accessed on the Company's website at http://www.neurocrine.com which will link you to the UBS Conference site. Once you have been linked to their site, you have the option to search by company name, or by time and date to access the webcast.

If you are unable to attend the webcast and would like further information on this announcement please contact the Investor Relations Department at Neurocrine Biosciences at (858) 617-7600. Viewers are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software. A replay of the presentation will be available approximately three hours after the conclusion of the live event and will be archived on the website for two weeks.

About Neurocrine

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome (IBS), anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH) and other neurological and endocrine related diseases and disor
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
2. Neurocrine Biosciences Reports Second Quarter 2008 Results
3. Neurocrine Biosciences Announces Conference Call and Webcast To Present Second Quarter 2008 Financial Results
4. Neurocrine Biosciences to Present at the 2008 Citi Investment Research Global Health Care Conference
5. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2008 Financial Results
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2007 Financial Results
7. Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer
8. Neurocrine Announces Work Force Restructuring
9. Neurocrine Receives Approvable Letter for Indiplon Capsules with Additional Safety and Efficacy Data Required by FDA
10. Neurocrine Biosciences Announces Conference Call and Webcast to Provide Indiplon Update
11. Neurocrine Biosciences and Dainippon Sumitomo Pharma (DSP) Announce Agreement to Develop and Commercialize Indiplon in Japan

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... Health care employment ...ins the only one to show consistent growth during ... hospitals remain in trouble, and health systems a... personnel, instead of just administrators. , ...Health care employment continued growing in Octobe...
(Date:11/24/2009)..., , SAN MATEO, Calif., Nov. 24 /PRNewsw..., a biopharmaceutical company focused on developin...ies, announced today that Anthony DiTonno, Preside...esent at the 21st Annual Piper Jaffray Health Care...New York Palace Hotel in New York, New York. ,...
(Date:11/24/2009)... The FBI recently approved...oratories participating in or generating DNA recor... Madison, WI USA (PRWEB) -- The FBI ...S System for use by laboratories participating in...Index System (NDIS). NDIS currently contains more ...
(Date:11/24/2009)..., , DUBLIN, November 24 /PRNewswire-Fi... the global specialty biopharmaceutical company, t...European Medicines Agency for,velaglucerase alfa, ...pment,for the treatment of Type 1 Gaucher disease....lucerase alfa that has been submitted, with previo...
Breaking Biology Technology:The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 4
... 15 VION,PHARMACEUTICALS, INC. (Nasdaq: VION ) t...due August 15, 2007 on its 7.75% Convertible Senio...cipal amount of the Notes is $60,million. The Com...suance of,shares of its registered Common Stock. A...es of Common Stock, based on today,s closing bid p...
.... 16 Cancer patients fraught with,flare-ups of pa...sistance,in the form of a new easy-to-use oral dru...s designed to quickly deliver pain medication. Ca...ain: persistent and,breakthrough. Persistent cance... for long periods of time, and often most of the d...
.... 16 Cepheid (Nasdaq:,CPHD) today announced that ...der with Northrop Grumman for the purchase of up t...t cartridges and associated materials. The,anthrax...tems (BDS),installed at United States Postal Servi...agreement covers the USPS fiscal years of 2007 thr...
Other Biology Technology:Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes 2Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes 3Novel Technology Breaks Through Cancer Pain 2Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems 2Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems 3
(Date:11/24/2009)...2009) -- The Wildlife Conservation Society (WCS) a...maining population of Siberian tigers has likely d...aching and habitat loss. , WCS says ...hat needs to be done to protect remaining populati...he report was released by the Siberian Tiger Monit...
(Date:11/24/2009)... research on bacterial communities throughout six ...temporal patterns, suggesting that scientists coul...climate change in the polar regions. The study, pu...nal Academy of Sciences Early Edition, shows that...ynchronously over time, correlating with seasonal ...
(Date:11/23/2009)...ted strain of the deadly superbug MRSAan infection...ticsposes a far greater health threat than previou...cording to a study in the December issue of Emerg...asily picked up in fitness centers, schools, and o...urden of MRSA within hospitals, the report found. ...
Breaking Biology News(10 mins):Report shows dramatic decline in Siberian tigers 2Researchers establish common seasonal pattern among bacterial communities in Arctic rivers 2New study finds MRSA on the rise in hospital outpatients 2Greenberg Traurig Attorney Selected For Massachusetts Life Sciences Collaborative Task Force 55324 1Greenberg Traurig Attorney Selected For Massachusetts Life Sciences Collaborative Task Force 55324 2CareFusion Corp to be Included in S 26P 500 Index 55322 1CareFusion Corp to be Included in S 26P 500 Index 55322 2Help Save a Life Bone Marrow Donor Registry Drive Sept 2 at the Karmanos Cancer Center 55320 1Help Save a Life Bone Marrow Donor Registry Drive Sept 2 at the Karmanos Cancer Center 55320 2Help Save a Life Bone Marrow Donor Registry Drive Sept 2 at the Karmanos Cancer Center 55320 3Help Save a Life Bone Marrow Donor Registry Drive Sept 2 at the Karmanos Cancer Center 55320 4
...asing ocean acidification has often focused on its...ruptions of biological processes in the oceans may... professor of ecology and evolutionary biology at ...xpert in coral reef ecology and marine biodiversit...ogical Responses to Ocean Acidification" at the Fa...
...at may hold clues to improving the success of isle...s, according to a Medical College of Georgia scien...lin-producing cells causing high blood glucose lev...r. Rafal Pacholczyk, an immunologist in the MCG Ce... just received a three-year, $495,000 grant from J...
...ster have designed a gene that produces a thousand...y cells., The findings may help address the prime ...ents, ability to specifically and effectively targ...ts should be able to insert "self-destruct" codes ...ll themselves while healthy cells remain largely u...
Other Biology News:Ocean acidification could have broad effects on marine ecosystems 2High blood sugar's impact on immune system holds clues to improving islet cell transplants 2High blood sugar's impact on immune system holds clues to improving islet cell transplants 3Modified gene targets cancer cells a thousand times more often than healthy cells 2Modified gene targets cancer cells a thousand times more often than healthy cells 3
DNA Sequencing Service from Yorkshire Bioscience Ltd
Mouse Anti-LAT Monoclonal Antibody, Unconjugated, Clone LAT1111 from BioLegend
Nuclear / Cytosol Fractionation Kit from MBL International
Cytosol / Particulate Rapid Separation Kit from MBL International
Biology Products: